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Abstract
Background: The clinical features of SMA, which range along a spectrum of severity, are relatively well described.
In contrast, the literature on how individuals with SMA and their families experience this condition is limited. To
address this gap, we undertook a qualitative study with individuals affected by SMA Types I, II and III, parents of
those affected, and clinicians.
Methods: We completed 16 focus group sessions and 37 interviews in the US with 96 participants including: 21 with
individuals with SMA; 64 parents of individuals affected by SMA; and 11 clinicians who specialize in the care of
SMA patients.
Results: The Diagnostic Journey: Families reported substantial diagnostic delays owing to: 1) lack of awareness
and knowledge about SMA; 2) the difficulty of distinguishing normal from abnormal development; and 3) the
challenge of differential diagnosis. Lack of sensitivity in how clinicians communicated this potentially devastating
diagnosis compounded parents’ negative impressions.
Newborn Screening: Parents generally held positive views about adding SMA to newborn screening panels. For
example, it would: 1) enable earlier access to care; 2) shorten the diagnostic journey; and 3) give families more
time to prepare to care for a disabled child. Some noted negative outcomes such as prematurely affecting a parent’s
relationship with a child before symptoms are evident.
The Psychosocial Impact of Living with SMA: Ten thematic areas characterized the impact: 1) confronting premature
death; 2) making difficult treatment choices; 3) fearing the loss of functional ability; 4) coming to terms with lost
expectations; 5) loss of sleep and stress; 6) stigma; 7) limitations on social activities; 8) independence; 9) uncertainty and
helplessness; and 10) family finances.
Conclusions: The results of this study suggest high levels of burden experienced by individuals with SMA and their
families. The difficulties of living with SMA begin with the long and often arduous process of finding a diagnosis for
their child. Newborn screening for SMA is seen as an important step toward shortening this journey. The psychosocial
effects of coping with SMA are substantial and wide ranging both for the individual living with this condition and
family members of affected individuals.
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Background
Spinal muscular atrophy (SMA) is an autosomal reces-
sive disorder; in almost 95 % of all cases, there is a
homozygous deletion or mutation of the Survival Motor
Neuron 1 gene (SMN1) [1, 2]. SMA is characterized by
degeneration of alpha motor neurons in the spinal cord,
resulting in progressive muscular weakness and atrophy
[3–5]. Affecting approximately one in 10,000 live births,
SMA is a leading fatal autosomal recessive disorder in
infancy [6–8].
SMA is classified into three main phenotypes, strati-
fied by age of onset and severity of disease [5]. Some
experts use an expanded classification system that in-
cludes a fourth phenotype to distinguish adult onset SMA
[5, 9]. The most severe form (Type I) represents approxi-
mately 60 % of incident SMA cases and symptoms usually
present within six months of birth [5, 9, 10]. Individuals
with this form generally experience severe muscle weak-
ness and atrophy, and some develop difficulty swallowing.
They usually require ventilatory support and most die
before the age of two [11–13]. SMA Type II accounts
for approximately 30 % of SMA cases. These patients
generally experience less severe proximal muscle weak-
ness than observed in Type I SMA, and symptom onset
is relatively delayed, usually evident by 18 months of
age. Patients often can sit unaided, but never gain the
ability to walk. Other common characteristics of SMA
Type II include impaired swallowing, breathing, and de-
velopment of scoliosis [5,10] Many survive into adult-
hood, but life expectancy is shortened compared to the
general population, often because of respiratory failure
resulting from lung disease, which increases in severity
with age [11].
Approximately 10 % of SMA cases are classified as
SMA Type III [10]. SMA symptoms tend to be milder
compared with Types I and II, appearing anytime
between 18 months of age and adulthood [5]. These
patients have a normal lifespan [5]. Patients may initially
walk or stand unaided; however, as the patient ages,
proximal muscle strength becomes progressively weaker,
and patients might need assistance to stand or walk.
Accordingly, after age 2, patients begin to experience
frequent falls and fatigue [5, 11, 14, 15]. Type IV, the
mildest form, is rare. Individuals with this form do not
exhibit muscle weakness until adulthood [16].
Evidence suggests that earlier initiation of supportive
therapies can improve outcomes [2, 17, 18]. Despite the
fact that a genetic test is available for newborn screening
(NBS) [11], diagnostic testing currently is performed
only when a clinician recognizes symptoms, often delay-
ing diagnosis [2, 19]. Beyond a single study in Australia,
which noted the negative impact of diagnostic delays
[20], little is known about how families arrive at a diag-
nosis of SMA, how delays effect the disease trajectory,
or a how a delay impacts a family’s ability to care for
their child.
SMA can be a devastating disease, yet there is limited
knowledge on how the disease affects the lives of indi-
viduals and families. Some studies have indicated that
patients and families experience a lower quality of life
and higher levels of stress [21–24]. However, much of
this literature is based on studies conducted outside of
the United States and does not offer an in-depth exam-
ination of perceptions about life with this disease and
the associated burdens.
Here we report on one part of a larger study to under-
stand the effect of SMA on the lives of individuals with
this condition and their families and what would consti-
tute meaningful improvements or decrements in func-
tion. In this report, we examine: 1) Factors that affected
how families arrived at a diagnosis, as described by
parents and clinicians; 2) Parents’ views on newborn
screening; and 3) The impact of SMA on the lives of in-
dividuals with SMA and their parents.
Methods
This study employed qualitative methods to elicit the
views and experiences of individuals with SMA, parents,
and clinicians who care for SMA patients in their own
words. From June to October 2014, we completed 16
focus groups: 7 in connection with the Cure SMA
national convention and 9 across five clinic locations
(Denver, Boston, Palo Alto, Cincinnati or Chicago). We
chose the sites because they were linked to Cure SMA
chapters with active memberships with leading SMA
clinicians. In addition, we conducted 37 semi-structured
telephone interviews with individuals with SMA, parents
or clinicians who could not attend the focus groups.
To recruit participants, we sent email invitations to
1,052 SMA families and clinicians identified through
Cure SMA mailing lists and supplemental e-mail blasts
to members and chapter leaders of SMA advocacy orga-
nizations. Individuals were eligible for the study if they:
a) had SMA Type I, II, or III b) were a parent of a child
with SMA Type I, II or III, aged one to 25 years alive
within the past two years; or c) were a clinician involved
in SMA clinical trials and caring for SMA patients at
least 20 hours per week.
Study participants 12 years of age or older signed an
informed consent document, and those 11 years of age
or younger signed an assent document prior to the start
of an interview or focus group. We obtained parental
consent for individuals under age 18 years. Study partici-
pants did not receive honoraria or any form of compen-
sation. The Ethical & Independent Review Services
institutional review board (IRB) approved the study
protocol (Reference #: 14051–01).
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A trained interview/moderator conducted the focus
groups (60–90 minutes long) and telephone interviews
(30–60 minutes) using a semi-structured guide (See
Appendix). Each session was audio-recorded and tran-
scribed for analysis. The questions covered ten do-
mains: 1) obtaining a diagnosis; 2) views on newborn
screening; 3) the impact of SMA on the individual and
the family; 4) treatments and avoiding hospitalization;
5) respiratory care; 6) declines in motor function over
the preceding twelve months; 7) meaningful changes in
motor function; and 8) expectations about improvements
resulting from treatment. For the final two domains
participants were asked to comment on items of the Ex-
panded Hammersmith Functional Motor Scale (HFMSE)
and any improvements in function that were not already
captured by this scale [25–27]. For the purposes of this
publication, we focus on domains one, two and three;
findings related to the remaining areas will be described in
a future publication.
Consistent with grounded theory [28, 29] two analysts
independently read the transcripts, identified core con-
cepts, and then jointly created a start-list of codes with
definitions. One analyst then applied the codes to text
segments within each transcript and both analysts
reviewed the coding and revised the code list as neces-
sary. Two additional coders independently coded 10
percent of the transcriptions and any discrepancies
between the initial coding and the secondary coding
were reconciled. Finally, we identified unifying themes
that characterized participants’ experiences and views.
We employed Dedoose [30], a qualitative analysis soft-
ware package, to facilitate the coding and management
of text segments. Saturation analysis showed that no
new concepts emerged in the final 10 percent of the
interview/focus group sessions suggesting that we fully




A total of 136 individuals responded to the recruitment
emails and were screened for eligibility, 126 individuals
were eligible, and 96 individuals participated in the
study. Of the 96, 21 were individuals with SMA who
were approximately evenly divided by gender and ranged
in age from 8 to 46 years with the majority less than
18 years old (Table 1). The majority had SMA Type III
and almost two-thirds were non-ambulatory. The 64
parents of individuals with SMA were predominantly
female and their children with SMA ranged in age from
10 months to 20 years. Most had children with SMA
Type II. Children of four of the parents were deceased
due to complications of SMA. In two cases both parents
of a child or a grandparent and a parent of a child
Table 1 Characteristics of the 96 study participants
Characteristics Number (%)










Type I 1 ( 5)
Type II 8 (38)






Focus Group 11 (52)




Age range of child with SMA (yrs)
<1 year 5 (8)
1–2 years 6(9)
3–11 year 30 (47)
12–17 19 (30)
18–25 5 (8)
Mean age of diagnosis (yrs.) 2.05
SMA type
Type I 12 (19)
Type II 29 (45)
Type III 22 (34)
Form of participation
Interview 21 (33)





Care for multiple SMA types
Yes 10
No 1
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participated together in a focus group. The 11 clinicians
were predominantly male and had, on average, almost
21 years in practice. Most were pediatric neurologists
and ten had practices that covered the SMA spectrum.
Arriving at a diagnosis of SMA
The amount of time between the recognition of symp-
toms consistent with SMA and arriving at a diagnosis
varied, but finding a diagnosis was a long process for
many, requiring numerous visits to their pediatrician
and specialists. Only those who lived close to medical
centers with clinicians knowledgeable about SMA re-
ceived a diagnosis relatively quickly, while others, par-
ticularly those who lived a long distance from large
medical centers, endured weeks of testing and waiting
for results. Below we outline three themes that charac-
terized factors contributing to diagnostic delay.
Lack of awareness and knowledge about SMA
Although SMA is rare disease, it is common enough that
larger pediatric practices could encounter a child with
this disorder. One clinician in this study observed:
…the incidence of the disease is such that every
pediatrician is on average going to have one chance to
blow the diagnosis in their career and unfortunately
many of them take advantage of that opportunity [3]
While this comment may overstate the prevalence of
SMA, it emphasizes the point that most pediatricians
are poorly prepared to identify SMA as a potential diag-
nosis among children who evidence symptoms.
The lack of knowledge among primary care clinicians,
and even some neurologists, made it difficult for families
to find a diagnosis. A parent of a child with Type III
SMA described this challenge:
…we spent 3–4 years trying to find a diagnosis and we
didn’t have any luck so we were jumping from doctor
to doctor… the local doctors, they didn’t have a clue of
what could be wrong so we basically were struggling to
find somebody to help us understand the problem [11]
Parents often had to find information on their own or
had to advocate for additional testing and assessment. A
number reported that they succeeded in getting their
children referred to a specialist only after they produced
information from internet searches that might help to
explain the symptoms of their children or pushed hard
enough for additional assessments after being encour-
aged by friends or family to seek answers.
Not surprisingly, many parents were unaware of SMA
prior to their child’s diagnosis, unless they had another
child with this disorder. As a result, parents sometimes
failed to recognize even significant deficits in motor
function, a particular problem for first time parents with
limited experience with infants. A clinician described be-
ing surprised when he found that the parents of a young
infant were not aware of the profound abnormality of
their son’s inability to move his limbs.
… So I had a child not long ago whose parents at
3 weeks of age thought that child…had a problem with
one hand because he couldn’t bring it up to the mouth
and when I unwrapped the baby…he essentially, he
couldn’t move anything except barely get one hand to
the mouth and the other side was below that threshold.
I was amazed that they didn’t imagine anything would
be wrong because this is the first time they had ever had
a baby and that they thought that’s the way babies
were. So I stunned them with the information that there
actually was something terribly, terribly wrong. [3]
Distinguishing normal from abnormal development
One theme that emerged was the challenge of distin-
guishing normal from abnormal development in infants
and young children, a distinction necessary to initiate
the path to diagnosis. One clinician explained:
The usual situation is just that there’s some fall off
usually compared to either family members or peers in
terms of motor function, and depending on whether its
Type I, Type II, Type III, or whatever. It’s going to occur
at different ages and as a consequence be demonstrated
by age specific expectations. So the SMA1 kids maybe
start seeming like they are gaining head control, but
then they don’t fully gain it. Or they don’t develop the
ability to roll over or whatever. [4]
However, parents reported that they and the pediatrician
often could not tell if the baby simply had a developmen-
tal delay because there is a large range of what is consid-
ered to be “normal” development. Commonly, parents of
Table 1 Characteristics of the 96 study participants (Continued)
Years in practice (average, range) 20.7, 12 -28
Practice area/specialty
Physical therapy (neurological conditions specialty) 1 (9)
Pediatric physical therapy 2 (18)
Pediatric neurology 4 (36)





Focus group 4 (36)
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SMA Type I or II babies reported that they wondered if
there was something wrong early on and brought up their
concerns at regularly scheduled well-baby appointments,
but the pediatrician was reluctant to refer them to a spe-
cialist. A parent of a child with Type II SMA recalled a
common refrain: “’this is just developmental, come back
and see me in two months’.” A parent of a Type I child
described her experience with this problem:
….So after one month I brought it up to a pediatrician
and my son was 9 pounds and 2 oz when he was born,
so our doctor said ‘well you know he’s a bigger baby,
it’s sometimes harder for bigger babies to lift their
heads simply because they’re heavier. So let’s give it
one more month because of that’s within the typical
range development…[10]
Parents tended to defer to the judgment of the phys-
ician, and set aside their own fears, if only temporarily.
One parent of a Type II child described how the pedia-
trician’s lack of information combined with their own
inexperience resulted in a long period between the ap-
pearance of symptoms and arriving at a diagnosis.
… So we didn’t have the best feeling but we were first
time parents, and that’s what we’ve been told. You
know, you’re first time parents, listen to what everyone
else has to say and it will all be in time ok, but it
wasn’t. [37]
Parents of children with SMA Type III reported that
their children appeared to develop normally until they
reached an older age. Like their SMA Types I and II
counterparts, they tended to ascribe early appearances of
motor function deficits to natural differences between
children. One parent recalled that when her son was
fourteen he told her his hands were shaking and he had
difficulty getting up off the floor. She reported,
“He developed normally until about age ten or eleven,
we noticed some differences but we were not concerned.
We thought it was his unique body type and
coordination.” [47]
The challenges of differential diagnosis
Several parents of Type III children reported that their
child showed signs of muscle weakness but the clinicians
erroneously attributed these symptoms to other condi-
tions, such as muscular dystrophy. One mother said:
…the [local] neurologist…he didn’t actually
understand exactly what was going on. His first
impression or his only fear was that it could be
muscular dystrophy. [11]
Some children in this study had other chronic illnesses
that masked the symptoms of SMA or they had been
treated for other illnesses that led the parents or clini-
cians to attribute the symptoms of SMA to side effects
of those medications, delaying a correct diagnosis. For
example, one parent attributed her daughter’s weakness
to the multiple medications required to treat kidney
disease. The diagnosis of SMA was made when her
daughter’s strength did not improve after stopping these
medications.
Delivering the diagnosis
Parents reported a variety of ways that providers deliv-
ered the news about their child’s SMA diagnosis. Some
complained that the clinician informed them of the diag-
nosis in a perfunctory phone call or short office meeting.
Many of them felt that their doctors communicated the
diagnosis in an insensitive and unhelpful manner. This
style of communication was particularly hard for families
when they were given news that was often unexpected
and had weighty implications for their lives. A parent of
a child diagnosed with Type II SMA described this
experience:
“She (the neurologist) looked at our son and evaluated
him for probably no more than 3 minutes or less, and
then said ‘please sit down. I’m 99 % sure your child
has this condition and it’s terminal.’ So probably being
in the room all of five minutes, they told us that our
happy smiling gurgling child was going to die, and
then she said ‘there’s nothing we can do.’ So we sat
there in shock.” [2]
Physicians, in comparison, spoke of the difficulty of
communicating such “devastating news for the family,”
especially because most parents have never heard of this
condition.
“If you get the diagnosis of spinal muscular atrophy,
it’s definitely a devastating kind of news for the family.
Particularly either Type 1 or 2 that you have to really
tell the family the nature of the disease, the outcome,
and many times it’s definitely impacting suddenly
their whole lives… initially they cannot imagine what
they will face in terms of care for a child or the impact
of the disease. Not just for the child, but for the family,
too. I think it’s a difficult diagnosis.” [8]
Views on Newborn Screening (NBS)
As shown in Table 2, five themes reflected positive views
about NBS and three characterized worries. The most
common, raised by parents across the three SMA types,
was that NBS accelerated access to care, enabling them
to connect with specialists and begin treatment as early
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as possible-earlier than they would have without the re-
sults of screening. In their view, starting physical therapy
or nutritional and respiratory care as soon as possible
was necessary to enhance a child’s abilities, minimize
poor outcomes, and potentially prolong life.
Some parents explained that information from NBS
would shorten the time it takes for a family to find a
diagnosis for their child. This was particularly valuable
given the challenges of diagnosing SMA. Parents of chil-
dren with Type II SMA commented that receiving the
results of NBS would be particularly helpful to first-time
parents who may not know enough about expected
developmental milestones to be able to recognize the
symptoms of SMA early on.
Parents across the three SMA types believed screen-
ing results would help them to prepare to care for a
child with physical disabilities. These included psycho-
logical preparations, finding support groups, as well as
making preparations such as purchasing the necessary
equipment, finding a home that is more handicapped-
accessible, and making arrangements with insurance
providers to insure coverage of extra expenses.
Fewer parents noted negative implications of NBS and
those who did were primarily concerned that the results
would negatively impact their relationship with their
child. One parent believed that she would have been
constantly vigilant, waiting for symptoms to appear if
she learned of this diagnosis at her child’s birth. She
likened this to waiting for a sign to appear as “living on
the precipice of something bad all the time” and specu-
lated… “I don’t know that I would want that.” Another
worried that diagnosis prior to the onset of symptoms
would take away her opportunity to have “a normal time
together where I just got to enjoy my child.” [5] In a simi-
lar vein, a parent of a child with Type III wondered if
there might be some individuals who have a mild form
of SMA that would never be diagnosed and the results
of NB screening would unnecessarily burden them with
the knowledge that they have a very mild form of this
disorder. One questioned the cost-benefit of screening
for a rare disease.
The psychosocial impact of SMA
The parents in this study described how the all-
consuming nature of the demands of caring for a child
with substantial physical needs affected the emotional
and social lives of their entire family. As one parent
said, “It changes your whole life.” [9] The never-ending
nature of these demands took an emotional and a social
toll on families including the siblings, as one mother
explained:
“For me it’s been real, real depressing. It’s taken a
whole toll on my family. It is—I have to be able to
accommodate to his needs without making my other
two kids feel left out.” [12]
Table 2 Parents’ views about newborn screening
Themes Illustrative quotations
Positive Early access to care … it would be helpful because if you found right away if SMA was present, then I think that you
can be more proactive and start with all the therapies and whatever kind of nutrition would be
needed for whatever type that you have [9]
Shorten time to diagnosis But some families they go to the doctor… their son, he’s not lifting his head ok we’ll give it
another month, I think it’ll be okay give it another month, I guess I will do some testing, and
sometimes their child has SMA type 1 and they don’t find out until they’re a year old. So I think
that in those cases, in places that are not, that don’t have doctors that know about SMA, I think
that it would be for raising awareness of SMA the screening, the newborn screening would be
very beneficial. [10]
Prepare to care for a disabled child …. And also as a parent you’re preparing yourself both socially and psychologically to be ready
for what’s to come ahead. [9]
Help first-time parents who may not know
developmental milestones
I think that’s a really wonderful idea because like I said the strongest thing for us was we were
first time parents, we weren’t sure what was going on. …SMA is something we weren’t expecting
and especially when the disease is so devastating, you know? It makes such a huge impact in
your life, and the kid, not just a normal life but the mental health, physical, emotional,
everything. [26]
Want information if it is available Well I’m always for access to more information in general; I think it should be an option,
absolutely. [44]
Negative Prematurely affect my relationship with my
child
…I don’t know that I would have wanted to know and look at everything like ‘Oh no is that a
sign of SMA?’ [47]
Better not know in cases with very mild
symptoms.
On the other hand I suspect there are people that have SMA that…they almost never find out or
they’re so much older when they find out. They were better off not knowing…I’m not sure [7]
Cost-benefit of population wide screening
for a rare disease
I think that I understand the reasoning why there is not newborn screening for SMA simply
because it only effects 1 in 6,000 so I can understand that it’s very expensive to do for 1 in 6,000
babies then 5, 999 would not have it but I think that if we had all the resources in the world
then absolutely. [10]
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Ten thematic areas characterized the psychosocial
effects of living with SMA described by participants in
this study. Illustrative quotations for each theme are in
Table 3. Most of the areas affected both individuals with
SMA and their parents although some were more rele-
vant for parents, such as coming to terms with lost
expectations for their children. All of the themes were
pertinent across the three SMA types but like the SMA
phenotype, the effects associated with each area lay on a
continuum of severity, with the most severe typically
described by parents of children with Type I SMA and
the least severe by families and children with Type IIII
SMA. One clinician described this:
Again it depends on the level of severity of the disease,
so in the more mildly affected the impact can be fairly
minimal. The oldest patient I have was 84 when she
walked into my office. The impact on that family was
almost non-existent. For SMA1 families the impact is
really quite profound. [4]
Confronting premature death
Facing premature death is one of the most unimaginably
challenging outcomes of this condition for families and
individuals with SMA. This was not unique to Type I
SMA; for example a mother of a child with Type III
SMA expressed her fears about early death. A clinician
also described treating an adolescent with SMA Type III
who was depressed and thinking about death.
Difficult treatment choices
Families and clinicians described the difficult treatment
choices that some families faced, such as whether to
pursue an invasive treatment regimen for a child whose
respiratory function is failing. Based on their family’s
values, a family might choose palliative care with no in-
vasive treatments, some invasive treatments, or they
might pursue all available treatment options. One family
in this study did not elect to use respiratory support for
the baby with Type I SMA because they feared that
their child’s quality of life would suffer unacceptably.
Others chose to utilize all measures available, even
though they realized that they could not be certain
about what their child’s future might hold, and that
caring for their Type I child would be a major under-
taking for the entire family.
Heartbreak and fear with loss of functional abilities
Parents and individuals with SMA described living with
the constant fear of diminished physical function as the
condition progressed and the sadness associated with
these losses. Parents said that watching their children
decline was terribly difficult emotionally. For example,
one described the heartbreak of watching her son lose
his ability to smile, laugh and communicate joy. An
adult patient talked about the difficulty of learning to
accept her losses and giving up activities such as eating
out at a restaurant with friends.
Coming to terms with lost expectations
Parents talked about coming to terms with lost expecta-
tions for their children and experiencing “a lot of grief a
lot of letting go of things that I had hoped for my child”
[7] after learning about the SMA diagnosis and realizing
their child would never be like other children who do
not live with a deteriorating condition. For one parent
this meant learning to deal with conflicting feelings of
deep love for her child and the sadness brought to her
life because of his condition.
Loss of sleep and stress
Loss of sleep and the never-ending burdens of caring for
a child with substantial physical disability were a con-
cern. Many children required high levels of physical care
and constant supervision, day and night. Some described
how these physical demands became increasingly diffi-
cult to manage as the child grew in size. Many parents
had to awaken multiple times during the night to help
their child rollover to prevent bedsores, or even to sim-
ply adjust the covers to prevent the child from getting
too hot or cold.
Social discomfiture and stigma
In addition to facing the daily challenges of their chil-
dren having a physical disability, individuals with SMA
experienced social discomfort and stigma such as their
embarrassment when they could not perform physical
activities. Some patients described their frustration with
lack of handicapped accessible services, and frustration
with being stereotyped and treated differently than
others without a physical disability.
Limitations on social activities
Both parents and patients described how they were lim-
ited in their ability to socialize and engage in activities
outside of their homes for several reasons. Some chil-
dren required a lot of equipment to support their
breathing or movement making preparation for activities
outside of the home time consuming and overwhelming.
A family of a child with milder disabilities described
how they loved to hike but had to stop when their
daughter required a wheelchair. Others described how
the need to protect their child from respiratory infec-
tions required them to limit outdoor activities or even
keep their young children out of school. Finally, patients
were frustrated by lack of handicapped access or limited
ability to socialize because of weakness and fatigue.
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Table 3 Thematic areas: psychosocial effects of life with SMA
Thematic areas Illustrative quotations
Confronting premature death …we have a circle letter with 24 people and we know them all. So there’s constantly Type I’s dying in our circle
and [my son] knows he has SMA so every now and then this will come up ….Jesus isn’t coming for me yet and I
say no… [51]
My fears are that my son’s going to die early. [47]
…who’s just horribly depressed …is on anti-depressant medicines because he and he thinks about dying and all
of that. [5]
Difficult choices My husband and I chose not to do any invasive treatment with our daughter, that’s why she died so soon. She did
have a g tube, a feeding tube. We did use a suction machine, we rarely used an oxygen tank. Other than that,
nothing more, so she had a lot of trouble breathing and ultimately, that’s what took her life. But for us, it was
quality over quantity. And I had heard from many other families who had Type 1 s, Type 2 s that have used trachs
and things like that, and it just wasn’t something that we wanted for our child. So, we made those decisions
because of that. [49]
…they said, ‘Our options are palliative-type hospice care,’ which basically means turn off the machines, that’s the
end, ‘or we can give him a trach.’ Our family decided that’s the route we were going to take. We gave him a trach.
We gave him a gastric feeding tube. We really didn’t know his future. We knew it would be a journey. We knew
that our lives would change forever. …Our house is like a miniature NICU. [43]
Heartbreak and fear with loss of
functional abilities
It’s frightening, and it’s so cruel because it declines and then you’ll plateau for a little while and every time you
plateau, you start to feel like ok, maybe we can hang out here for just a while but the scary thing is you never
know when the next decline is coming. So every day is just a fear of will today be the day and plus, every time he
loses some ability or every time his respiratory health declines, we always wonder what else he has to lose. [30]
…and sometimes it’s like oh screw it, I can’t do this anymore. You know, like the feeding myself. For a while, I’d
bring blocks that I’d put under the table at a restaurant to raise the table up, things like that. And then it got to
the point where I was struggling so much to eat, I’d choke more often and then having people feed me, I started
to choke more often. You know, like oh crap, I got to give this up [31]
Coming to terms with lost
expectations
…you’re basically dying to all those expectations that you had had… my son was the thing that brought me
such joy, you know, the person in my life that makes me feel happy, but then also looking at him reminded me of
the disease is the thing in our life he says that makes us unhappy. So it was hard to balance, you know, still being
a great mom and still encouraging and loving at the same time of grieving. So you know I gave myself time every
day to be sad to try and do it away from my son. [10]
Loss of sleep and stress He’s very dependent on me, and it’s driving me crazy…He won’t let his father or anybody else take him to the
bathroom or change him or feed him or anything. That drives me crazy personally because I never get a break. [12]
…You have to roll her over, we have to place her arms where they’re going to be when she falls asleep,” explains
the mother of a Type 2 patient. “Her head, her legs exactly how she wants them, and then she sleeps for a while,
she wakes up, calls, and you go in and roll her over and place everything again….(we have to move her) every
hour to an hour-and-a-half. [14]
Social discomfiture & stigma …he needs to read “The Great Gatsby” over the summer so we were in this little bookstore. …He walks in and the
man’s going ‘no, I don’t have it, oh, but get up, step up on this crate and get that book up there that might have
something.’ He (son) can’t do that. But the person didn’t realize it, so I got up and got it, but we didn’t go into an
explanation why I had to do it. And so that stuff, you know, you’re not going to grieve, but there’s a loss there.
Can’t step up on stool to get something, and you feel a little awkward when you’re as able-bodied as you look,
but yet something as simple as that you can’t do. [9]
I mean it’s hard to go out with a disability; it’s hard to make friends with a disability. At least now that I’m not in
a wheelchair I can kind of hide it, and it’s not as obvious… People treat you differently when you’re in a
wheelchair. [19]
Limitations on social activities That was a lot, it was extremely overwhelming. Especially because I wanted to take her outside, I wanted to go on
a walk; she was inside so much that it just wasn’t fair. It was difficult to move her because she would stop
breathing, just to change her diaper she would stop breathing, so it was really hard. I think once or twice I had
tried to take her out on my own; we lived in an apartment complex at that time that had a beautiful park. I
wanted to take her walking and I tried and she had a blue spell, and I had to somehow carry (her) inside. Now
she’s deadweight at this point and she was actually very, very long for her age so it was a lot to carry her and I
would always carry a morphine syringe filled with morphine anywhere I went because she would just stop
breathing. And just trying to do all that and manage the keys, just doing all that stuff all by myself. [49]
I actually went to a festival over the weekend and I needed to use a handicapped bathroom, and the only
handicapped accessible bathrooms in the whole entire place were for VIP. It’s like, ok, but I can’t use the stairs.
They couldn’t get it through their heads that they need a handicap accessible bathroom for everyone…Even my
friends will be like do you want to come to this party and it will be late at night, and I’m like, I already went out
today, I’m too tired. [19]
Struggle to achieve independence … he’s 17 in two months, he goes off to college in two years, that’s my hope. I fear he’s going to have to have a
parent at college just because there’s many things that he can’t do by himself. [47]
…I’m already worried about finding a job right now without a wheel chair…[19]
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Struggle to achieve Independence
Achieving independence was a worry for parents and in-
dividuals with SMA. For example, parents who wanted
their children to experience an independent life as adults
had to weigh this heavily against the reality of how much
assistance their child would need away from home and
what that assistance would cost. The mother of a 17-
year-old with Type II SMA was proud of her daughter,
who excelled in school and was applying to college, but
she worried about getting her the supportive care she
would need to aid her to dress, toilet, and shower while
away at school.
Uncertainty and helplessness
Parents said that in living with SMA they felt very help-
less and out of control, especially regarding the future.
They noted how the uncertain trajectory of the decline
in a child’s functional status or even life expectancy
made it difficult for them to plan ahead. One parent
explained the painful paradox of planning for a child to
die while planning for his or her future.
Pressure on family finances
Several participants described the financial impact of
having a child with SMA. A clinician estimated that the
cost of raising a child with a degenerative neuromuscular
disease was “in the millions, per child.” A mother de-
scribed the financial burden of lost income as a result of
taking time off from work or needing to re-arrange a
work schedule to accommodate the extra needs of their
child. Some parents experienced problems with obtain-
ing adequate support for their Type III children who
attended public schools. For example, several noted that
some states did not offer services for children who have
physical disabilities without cognitive impairment. In
some instances this forced families to make other
arrangements for schooling, which sometimes required
leaving their jobs.
Discussion
The results of this study augment the existing knowledge
about the journey to SMA diagnosis, views on NBS, and
the impact of SMA on those living with this condition.
The findings underscore the broad range of this impact
and the high level of burden families experience, and the
challenges individuals face in coping with this disorder.
Our findings highlighted two important challenges for
families seeking a diagnosis. First, the process can be long
and difficult and delays hamper prompt access to treat-
ment or participation in clinical trials [2]. Improving the
speed of diagnosis can mean earlier initiation of treatment
and help individuals with SMA Types II and III better
maintain motor function. Similarly, earlier diagnosis of
infants with SMA Type I means that interventions can be
initiated before a child becomes nutritionally compro-
mised and develop neurologic and respiratory damage
[11, 32]. In addition, earlier diagnosis can help parents
find the resources they need more quickly and better sup-
port their financial, social and psychological preparations
to care for a child with significant physical disability.
A second challenge of the diagnostic process for fam-
ilies is that the emotional effects of a prolonged diagnos-
tic journey are exacerbated when clinicians deliver the
diagnosis in an insensitive manner. These findings sup-
port those reported by Lawton and her colleagues [20]
about an Australian study and, to the best of our know-
ledge, the only other study to examine families’ experi-
ences in arriving at a diagnosis of SMA.
Table 3 Thematic areas: psychosocial effects of life with SMA (Continued)
Uncertainty & Helplessness The burden, I guess as parents, is just feeling helpless. Knowing that your child has a disease that there’s really not
much you can do about, and the options you do have are very, very scary and very invasive. And no matter what,
the disease will progress. I guess that was the initial burden, just knowing that this was going to happen and it
was basically a train wreck that you had no control over. [49]
…when you start this journey you really don’t think your child is going to live, and planning a funeral now for
13 years as well as you know saving for a college fund. So it’s a very bizarre mind trip that you’re going through.
But when majority of cases with SMA are Type 1 and unfortunately so many children do die, but when you’re
going along on this journey as a parent you don’t know what to plan for. We were in a tri-level home with a boy
in a wheelchair and no bedroom on the downstairs level, no bathroom, we didn’t know if he was going to live
though. If he wasn’t going to live do we move or do we not, you know. It wasn’t until he was 6 we moved to a
single story home. You don’t know how to plan. [2]
Pressure on Family Finances …At the beginning I took maternity leave, but I got some sort of compensation for that, but at the end, no. I was
very fortunate I have an employer that was extremely flexible and understanding. Not everybody’s like that, and I
can imagine that some people would lose their job, or their position or something would happen. I can’t imagine,
especially with a sick child. [49]
SMA children are not cognitively delayed, they’re just physically fragile. So that really leaves a gap in care,
because most funding sources require children to be both cognitively and physically disabled. That’s not the
case with a neuromuscular disease. Even though they need a lot of care, they’re not cognitively delayed. So that
means that this population is under, they’re lacking a safety net. … [state] does not support SMA families at all.
And that’s a real problem. Because without their support, the families are left to struggle, to leave their job to
take care of their child. [33]
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Difficulties with the diagnosis stem, in part, from lack
of awareness and knowledge about SMA and educating
parents, pediatricians and other clinicians about SMA
may help to alleviate delays. Studies by Rothwell [32]
and Meldrum [15] point out the need for better educa-
tion of parents about SMA both prior to genetic testing
and at the time of an SMA diagnosis. In addition, pedia-
tricians would benefit from increased awareness about
this disorder in general as well as training on how to
deliver news of a diagnosis of a life altering condition
such as SMA in a less negative, and more sensitive and
knowledgeable manner. Communicating about symptom
progression is difficult for any clinician talking with
patients about a serious illness, but it is even more chal-
lenging when discussing a condition that is virtually
unknown by the general public and where the symptom
trajectory is unpredictable, as it is with SMA.
The finding that most parents supported the addition
of SMA screening to universal NBS panels is consistent
with other studies. In a survey of parents of children
with neuromuscular diseases and unaffected expectant
parents, over 90 % of the participants supported NBS for
these conditions, including SMA [33]. In a qualitative
study on SMA NB screening, participants viewed screen-
ing to be of low risk and with potential benefit but they
felt that parents should have the opportunity to opt-out
of the screening [32].
In the United States, specific guidelines and processes
have been established by the Federal government for
adding diseases to the Recommended Uniform Screen-
ing Panel ( See http://www.hrsa.gov/advisorycommittees
/mchbadvisory/heritabledisorders/index.html for details).
It is important to note, however, that expanding these
panels raise ethically complex questions. Recommenda-
tions to include SMA in this panel should be considered
in light of three caveats. First, NBS information cannot
definitively predict the severity of the phenotype, the age
of onset of symptoms, or the trajectory of their child’s
condition. However, in the specific case of SMA, SMN2
copy number forecasts this, albeit not perfectly [34]
Second, approved pharmacological treatments are not
available at this time. When such treatments are avail-
able screening will become critical in order to treat
patients as early as possible, which has been shown to
be beneficial in mouse models of SMA [35] Currently,
the principal benefit of adding of SMA screening is to
shorten the time to diagnosis and to begin proactive
clinical care, which itself has been shown to alter the
natural history of type I SMA [36, 37]. Third, the deci-
sion to add SMA screening to NBS panels must also be
weighed against potential detriment to parents’ experi-
ences with their newborn prior to onset of symptoms, a
concern raised by a few parents in this study. However,
as discussed previously, previous survey results about
parental attitudes about NBS for SMA have been very
positive [15, 32].
The importance of understanding the emotional and
social effects of caring for a child with a disabling phys-
ical condition like SMA cannot be overemphasized.
Families and individuals with SMA face multi-faceted
challenges including feelings of loss and helplessness,
limitations on activities outside of the home, and finan-
cial concerns. Experienced alone, each of these effects
can have a significant impact on the quality of life of an
individual or family. Combined, they can seem insur-
mountable and sometimes uncontrollable. The psycho-
logical impact for individuals with SMA and their families
is complicated by the fact that the condition is progressive.
Parents and individuals with SMA described the painful
juxtaposition of waiting for functioning to decline while
struggling and hoping to maintain function. Uncertainty
about the trajectory of the condition made coming to
terms with this condition more challenging than it might
be otherwise.
Our findings are consistent with the reports of lower
quality of life reported by 35 families and children sur-
veyed in the Czech Republic [21], reports of higher rates
of stress and strain and lower rates of social supports
reported by parents of children with SMA in Germany
[38] and lower scores on the Pediatric Quality of Life
Inventory among 176 children with SMA compared to
healthy children [39]. A study of 37 adults with SMA II
who lived independently in Denmark found that these
individuals successfully managed their lives although
they lived with anxiety about the future and feared pro-
gressive decline in their motor function [40]. This sug-
gests that individuals with SMA can successful lives
given adequate supports such as those offered to families
in Denmark.
It is important to keep in mind that just as the clinical
features of this condition are highly variable, so are the
psychosocial effects of living with this rare disease [16].
For example, without effective treatment, parents of Type
I children can face choosing between invasive treatments
to keep their child alive past the first year or palliative
care. On the other end of the continuum, parents of Type
III children experience the stress of letting go of their need
to protect their child and instead prepare them to live as
independently as possible.
While our study sample was relatively small (21 pa-
tients, 64 parents, 11 clinicians), semi-structured inter-
views allowed us to obtain in-depth information about the
experiences of individuals living with SMA as expressed in
their own words. This is especially important given the
psychosocial nature of many of our research questions.
Our study offers a clearer understanding of the patient
journey to diagnosis across SMA types and identifies at
least two opportunities to shorten the diagnostic delay,
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i.e., educating clinicians to promote earlier diagnosis and
offering SMA newborn screening for those parents who
want it. In addition, this study enhanced our understand-
ing of complexity of this condition as well as its psycho-
social impact on individuals with SMA and their parents.
Several topics emerged which deserve broader investiga-
tion using quantitative methods. For example, a study
involving a larger sample of families and children affected
by SMA would provide more specific information about
the factors that affect the diagnostic journey, access to
supports, and family coping.
The experiences and views described by the participants
in this study reflect a self-selected sample recruited
through the SMA advocacy groups and may not reflect
the views of those not connected to these organizations.
Finally, because the majority of participants were parents
of individuals with SMA, our findings emphasize their
perspective more than the perspective of individuals with
SMA and clinicians who care for them.
Conclusions
SMA presents complex challenges for individuals with
this condition and their families. Researchers and clini-
cians have invested substantial effort into understanding
the genetic basis of this inherited disorder; its clinical
features and their management. Less attention has been
paid to understanding the effect on the lives of families
and individuals with SMA across the disease spectrum.
The results of this study reveals the considerable psy-
chosocial impact of this condition beginning with the
difficulties of the diagnostic process and views on how
newborn screening might ameliorate the process and
suggests important unmet needs for early diagnosis and
effective treatment.
Appendix
Questions Covered in SMA Focus Groups and Interviews
1. Let’s start by talking a little about what was happening
from the time when [YOU/YOUR PATIENT/THE
PERSON YOU CARE FOR] first had symptoms to
when they finally got diagnosed. How long did that
take and what was that like?
2. What has been the impact of SMA?
3. Do you think newborn screening of SMA would be
helpful?
4. What does it feel like for someone who might have
this condition?
a. [PROBE] What might someone who has this
condition experience?
5. Let me go up to the board, and let’s list some of the
ways that SMA [YOU/YOUR PATIENT/THE PERSON
YOU CARE FOR].
6. [FOR EACH LISTED] How big of an impact has
this had on [YOUR LIFE/YOUR PATIENT’S LIFE/
THE LIFE OF THE PERSON YOU CARE FOR]?
7. [IF NOTMENTIONED] Do [YOU/YOUR PATIENT/
THE PERSON YOU CARE FOR] do things/take
steps to avoid being hospitalized? Tell me about that?
8. Do [YOU/YOUR PATIENT/THE PERSON YOU
CARE FOR] do things/take steps to avoid [RES-
PIRATORY EVENTS/THINGS THAT MIGHT
IMPACT BREATHING]? Tell me about that?
9. In the past 12 months, what kind of decline in
motor function did [YOU/YOUR PATIENT/THE
PERSON YOU CARE FOR] experience?
10. Would a treatment that stops decline in motor
function be meaningful to [YOU/YOUR PATIENT/
THE PERSON YOU CARE FOR]?
11. Would a treatment that improves your motor
function be meaningful to [YOU/YOUR PATIENT/
THE PERSON YOU CARE FOR]?
12. What kind of improvement do [YOU/YOUR
PATIENT/THE PERSON YOU CARE FOR] want
to see from treatment?
13. Take a look at [CORRESPONDING ITEM FROM
HAMMERSMITH SCALE]. Would a partial im-
provement (i.e. 0 to 1 or 1 to 2) be meaningful?
14. What other changes from treatment be meaningful
to [YOU/YOUR PATIENT/THE PERSON YOU
CARE FOR]?
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